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Abstract
Systemic sclerosis (SSc) or scleroderma is a disorder of the connective tissue affecting
the  skin,  and  it  is  often  associated  with  visceral  involvement.  The  predominant
pathological features of SSc are autoimmunity, vasculopathy, and fibrosis. Progressive
fibrosis is associated with changes in the microcirculation of the involved organs. Here,
we review the  clinical  features  of  systemic  sclerosis  and describe  the  best  practice
approaches for its management, reviewing available guidelines and recommendations
and providing experts’ insights. 
Introduction
Systemic sclerosis (SSC) or  scleroderma is an autoimmune disorder of the connective
tissue  affecting  the  skin  that  is  often  associated  with  visceral  involvement.  It  is
characterized by excessive collagen deposition in the skin and internal organs, resulting
in  progressive  tissue  fibrosis  and  with  changes  in  the  microcirculation  leading  to
secondary Raynaud's phenomenon and obliterative vasculopathy.
Overall,  the  estimated  prevalence  is  25  cases/100,000,  the  incidenceis  0.06-1.9
years/100,000,  and it is prevalent in females (mean 4:1). In detail,  prevalence ranges
from  0.7/100,000  to  53/100,000  depending  on  demographics  and  the  country  of
residence, with higher numbers in the USA as compared to Europe or Japan. Age  at
onset is between 35 and 65 years (1,2). 
Pathogenesis is multifactorial  and includes genetic factors such asHLA (HLA A1, B8,
DR1, DR3, DR5, DR11), and environmental factors such as viruses (Cytomegalovirus,
parvovirus  B19),  ortoxic  substances  (silica,  silicone  prostheses,  polyvinyl,  benzene,
organic solvents, certain drugs, adulterated rapeseed oil)(1,2).
SSc has  a  highly variable  evolution,  ranging from  the acral-localized  form to  rapid
swelling lesions that spread quickly to all  areas of the skin including the trunk, and to
the visceral involvement (3).
SSc frequently  affects internal organs such as the lungs, heart and the gastrointestinal
tract (GI), all of which significantly contribute to morbidity and reduced quality of life
in  these  patients.  Overall,  the  prognosis  of  scleroderma  is  influenced by  visceral
involvement (especially of the lung), as well as cardiac and renal involvement.
Even if survival has improved considerably in the last thirty years, SSc has one of the
highest mortality rates among the rheumatic diseases. Cumulative survival  following
diagnosis has been estimated 74.9% at 5 years and 62.5% at 10 years. The common
causes of death are pulmonary fibrosis and pulmonary arterial hypertension (PAH) (4).
Overview of Current Guidelines and Recommendations 
SSc therapy is still difficult to manage and yet is not well defined. It must consider the
various pathways involved in the disease: activation of T lymphocytes, vascular disease
due  to  vasospasm  and  endothelial  immune  damage,  and  abnormal  stimulation  of
fibroblasts  resulting  in  excessive  deposition  of  extracellular  matrix.  Therefore,  SSc
therapy includes steroid and immunosuppressants, vasoactive drugs (vasodilators and
endothelial protectors), and anti-fibrotic agents. (5,6)
The  EULAR  has  published  in  2016  updated  evidence-based,  consensus-derived
recommendations for the treatment of SSc (7).
As compared to the previous (2009) EULAR recommendations for the treatment of SSc,
the updated recommendations  include several  new therapies  for  specific  SSc-related
organ involvement. The greatest changes have been made inthe  treatment of vascular
complications.  These  changes  include  the  introduction  of  phosphodiesterase  type  5
(PDE5)  inhibitors  for  SSc-related  RP  and  digital  ulcers  (DUs),  riociguat  and  new
aspects  of endothelin receptor antagonists (ERAs), prostacyclin analogues and PDE5
inhibitors for SSc-related PAH. New recommendations regarding the use of fluoxetine
for SSc-related RP were also added.
The task force consisted of 32 SSc clinical experts from Europe and the USA. All the
EULAR Scleroderma Trials  centers  and research groups  were invited to submit  and
select  clinical  questions  concerning  SSc  treatment  using  a  Delphi  approach.
Accordingly, 46 clinical questions addressing 26 different interventions were selected
fora  systematic  literature  review.  The  new  recommendations  were  based  on  the
available evidence andwere developed during a consensus meeting with clinical experts
and patients. The procedure resulted in 16 recommendations being developed (instead
of 14 in 2009) that address  the  treatment of several SSc-related organ complications:
Raynaud’s phenomenon, digital ulcers, pulmonary arterial hypertension, skin and lung
disease, scleroderma renal crisis and gastrointestinal involvement.
In  Raynaud’s phenomenon,  a  meta-analysis  of  randomized  control  trials  (RCTs)  on
dihydropyridine-type  calcium antagonists  indicates  that  nifedipine  (9-16) and  PDE5
inhibitors (Sildenafil, Tadalafil, Vardenafil) (16-22) reduce the frequency and severity of
SSc-RP attacks.  Oral nifedipine with PDE5 should be considered as first-line therapy
for SSc-RP.  A meta-analysis of RCTs on prostanoids indicates that intravenous iloprost
reduces the frequency and severity of SSc-RP attacks. Intravenous iloprost should be
used  for  the  treatment  of  SSc-RP  attacks  after  oral  therapy.  Fluoxetine  may  also
improve SSc-RP attacks (23). 
In digital ulcers in patients with SSc:  Two RCTs indicate that intravenous iloprost is
effective in healing digital ulcers in patients with SSc (24-25). A meta-analysis of RCTs
and results of an independent RCT suggest that PDE5 inhibitors improve healing of
digital ulcers in patients with SSc. 
In 2013, two meta-analyses compared i.v. iloprost, iloprost for oral use, trepronistil and
beraprost.  Authors  reported  that  small  sample  sizes,  few  comparative  trials,  and
heterogeneity limited the conclusions. However, the results suggested a role for PDE-5
inhibitors in the healing of digital ulcers; bosentan and i.v. iloprost may prevent their
recurrences (26-28). Moreover, the results of a small RCT indicate that PDE5 inhibitors
may prevent the development of new digital ulcers in SSc. 
Lately, the efficacy of bosentan in reducing the number of new digital ulcers has been
confirmed in two high-quality RCTs. Bosentan should be considered for  reducing the
number of new digital ulcers in SSc, especially in patients with multiple digital ulcers
despite  the  use of calcium channel blockers, PDE5 inhibitors or iloprost therapy  (29-
30).
In SSc-PAH:  Several ERAs (ambrisentan,  bosentan and macitentan) (31-33), PDE5
inhibitors (sildenafil, tadalafil) and riociguat have been approved for  the  treatment of
PAH associated  with  connective  tissue  diseases  (CTDs).  One  high-quality  RCT  on
patients with SSc indicates that continuous intravenous epoprostenol improves exercise
capacity,  functional  class  and  hemodynamic  measures  in  SSc-PAH.  Intravenous
epoprostenol  (2 ng/Kg/min)  should be considered for the treatment  of patients  with
severe SSc-PAH (class III and IV) since improvement has been seen in the Walk Test, in
NYHA, in the Borg dyspnea index, in pulmonary artery pressure (PAP), in right atrial
pressure, and in Cardiac index (34).
Other  prostacyclin  analogues  (iloprost,  treprostinil)  have  also  been  registered  forthe
treatment of PAH associated with CTDs.  Sitaxentan  use has been discontinued due to
hepatotoxicity.
In  Skin and lung disease:  Two RCTs and their re-analysis have shown that methotrexate
improves skin score in early diffuse SSc. Positive effects on other organ manifestations
have not been established (35-38).
Cyclophosphamide should  be considered  for  the  treatment  of  SSc-related interstitial
lung disease (ILD) (39-44).
Regarding  hematopoietic  stem  cell  transplantation  (HSCT), two  RCTs have  shown
improvement of skin involvement and stabilization of lung function in patients with
SSc,  while a third, large RCT reports improvement in event-free survival in patients
with  SSc  as  compared  to cyclophosphamide-treated  subjects.  HSCT  should  be
considered for the treatment of selected patients with rapidly progressive SSc at risk of
organ failure. Given the high risk of treatment-related side effects and early treatment-
related mortality, careful selection of patients with SSc for this kind of treatment and the
experience of the medical team are of fundamental importance (45-46).
In   scleroderma renal crisis (  SRC):  many studies have shown benefits in survival with
the use of ACE inhibitors in patients with SRC. Experts recommend the immediate use
of ACE inhibitors in the treatment of SRC (47-51). Glucocorticoids are associated with
a higher risk of SRC; therefore blood pressure and renal function should be carefully
monitored in these patients (52).
In  SSc-related  gastrointestinal  disease: the  experts  recommend  using  proton  pump
inhibitors (PPIs)  for  the  treatment  of  SSc-related  gastroesophageal  reflux  disease
(GERD)  and  the  prevention  of  esophageal  ulcers  and  strictures  (53-57).  Prokinetic
drugs should be used for the management of SSc-related symptomatic motility disorders
such as dysphagia, GERD, early satiety, bloating, pseudo-obstruction (58). Furthermore,
experts recommend using intermittent or rotating antibiotics to treat symptomatic small
intestine bacterial overgrowth in patients with SSc (59-60).
Comments on the guidelines 
After  reviewing  all  the  above-stated  topics  together,  some considerations  are  worth
mentioning. Other therapies  besides the  previously listed ones  have not been included
due to the insufficient number of studies. Some further information has been published
since the guidelines dissemination. This applies to:
a) Tocilizumab (162 mg/week subcutaneously) effective on the skin and lungs (61).
b) Mycophenolate mofetil compared to CYC in patients with SSc-ILD (62).
Lack of efficacy tests  does not  imply that  efficacy is  absent;  thus  the absence of  a
recommendation for a drug should not be interpreted as a contraindication for its use.
It  is  believed  that  these  up-to-date  recommendations  will  help  improve  the  care  of
patients with SSc in an 'evidence-based' manner and may point to a direction for further
clinical research.
Considering the complexity and heterogeneity of SSc and  the  limited evidence of  the
effectiveness of  treatments, it is recommended that patients with systemic sclerosis be
referred to specialized centers with appropriate management skills.
How I treat SSc: the experts’ opinion-the Padua Experience
The therapeutic approach to patients with Systemic Sclerosis (SSc) should be tailored to
their clinical manifestations and laboratory findings. First, it is important to define the
subset of SSc (i.e.,  diffuse or limited cutaneous form) [63] and the ANA specificity
(anti-centromere, anti-topoisomerase I, anti-RNA polymerase III) [64]. 
The limited cutaneous form is the most common subset of SSc and is characterized by
acral localized skin lesions (hand sclerodactyly and “scleroderma facies”).  The main
clinical  manifestations  in  this  form  are  ischemic  skin  ulcers and  subcutaneous
calcifications. Gastrointestinal symptoms are often present at an early stage, while other
visceral  involvement  is  not  frequent  and  slowly  evolving. The  only  exception  is
pulmonary arterial hypertension, which affects approximately 10% of patients and can
appear many years after SSc diagnosis [65].
The diffuse cutaneous form on the other  hand is  clinically  characterized  by rapidly
evolving  skin  lesions,  ischemic  ulcers,  concomitantinflammatory  manifestations
(e.g.arthritis,  tendonitis  and  myositis),  and  frequent  internal  organ  involvement
(pulmonary  fibrosis,  cardiomyopathy,  scleroderma  renal  crisis,  gastrointestinal
disorders), resulting in a poor prognosis for many patients [66].
Raynaud's phenomenon is the onset manifestation in  about95% of SSc patients.  Our
first  line  treatment  generally  consists  of  oral  vasodilators  (especially  calcium
antagonists) at maximally tolerated dose [8],  with the addition of intravenous iloprost
therapy in case of severe Raynaud's phenomenon [25].
Cutaneous lesions in patients with diffuse SSc may spread within a few months from
acrallocalized areas to almost the entire body surface, including the trunk. Given the
fundamental role that immune-mediated inflammation plays in the pathogenesis of these
lesions, we recommend initiating immunosuppressive therapy as soon as possible with
either  methotrexate  or  mycophenolate  mofetil  [36,  67].  To  potentiate  the
immunosuppressive  therapy,  SSc  patients  with  rapidly  progressive  cutaneous
involvement usually undergo long-term plasmaexchange in the Padua Rheumatology
Unit [68] to “slow down” disease activity.
Ischemic ulcers affect nearly50% of SSc patients in both cutaneous forms. Intravenous
iloprost is the only therapy that has proven to be effective in healing skin ulcers [69].
We recommend the use of antibiotics in case of ulcer superinfection. Treatment with the
endothelin receptor antagonist bosentan may help prevent and reduce the onset of new
digital ulcers in SSc patients [30,70].
Skin  ulcers  may  also  arise  from  subcutaneous  calcifications  which  can  reach  a
considerable  size  (“tumoral  calcinosis”),  most  notably  in  patients  with  the  limited
cutaneous form. Various drugs, such as colchicine and diltiazem, have been tested as a
treatment  for  calcinosis  though  with  poor  results.  Tumoral  calcinosis  often  requires
surgery [71].
The gastrointestinal tract is the internal organ most frequently involved in SSc, notably
the distal esophagus. GERD requires treatment with PPIs to reduce gastric acidity and
prevent esophagitis [53,72].  Prokinetic (promotility) drugs such as domperidone and
metoclopramide have shown poor efficacy in alleviating GI symptoms (dysphagia, early
satiety, abdominal distension, persistent constipation) [73]. Antibiotic rotation is very
useful  in  preventing  bacterial  overgrowth  which  can  cause  recurring  diarrhea  and
malnutrition in SSc patients [74].
The  past  fifteen  years  have  seen  the  advent  of  new  drugs  offering  substantial
improvements  in  the  treatment  of  PAH symptoms  and  hemodynamics  [75].
Administration  of  the  drugs  requires  a  definitive  diagnosis  of  PAH  by  cardiac
catheterization.  These  novel  agents  include  endothelin  receptor  antagonists,  PDE5
inhibitors, prostacyclins and recently, riociguat (soluble guanylate cyclase stimulator)
[76]. The NYHA functional class of the patient determines the choice of treatment (e.g.
patients in class IV NYHA show a significant response only to continuous infusions of
prostanoids) [18].  In  our  recent  experience,  macitentan  (an  endothelin  receptor
antagonist) is the treatment of choice for patients in classes II and III NYHA [31].
ILD remains one of the main causes of mortality in SSc, especially in patients with the
diffuse  form  [77];  therefore  treatment  with  immunosuppressive  drugs  ought  to  be
initiated in the early inflammatory stage (alveolitis) to prevent the deterioration of lung
function. We currently prefer mycophenolate mofetil over cyclophosphamide owing to
the  toxicity  of  the  latter  [39,78]. Stem  cell  transplantation  procedures  are  only
performed in few specialized centers now [46].  In case of poor clinical response or
intolerance,  patients  with  ILD  are  switched  to  rituximab,  a  specific  anti-CD20
monoclonal antibody [79].  Rituximab also appears to be effective in treating chronic
arthritis, another possible complication in patients with diffuse cutaneous SSc.
Cardiomyopathy, another visceral complication of diffuse SSc, should be treated even in
its asymptomatic phase.  However,  early diagnosis is challenging and requires cardiac
MRI.  The therapeutic  approach is  similar of  ILD and includes  immunosuppressants
such as cyclophosphamide, azathioprine or rituximab [80,81].
Scleroderma  renal  crisis  is  a  rare  organ  involvement  characterized  by  rapidly
progressive kidney failure that  may result  in  patients  requiring dialys is  within  few
weeks. The therapy is based on the use of maximum tolerated doses of ACE inhibitors
to  reduce  over-activation  of  the  renin-angiotensin  system,  to  control  arterial
hypertension and to prevent dialysis [47].  SRC can be triggered by vasoconstrictors
such as calcineurin  inhibitors  or  corticosteroids  at  high  doses,  and their  use  should
therefore be avoided altogetherin scleroderma patients [49]. The therapeutic protocol for
SRC that is performed in  the  Padua Rheumatology Unit  consists of a  combination of
high dose ACE-inhibitors  coupled with repeated plasma-exchange sessions,  especially
when  it  is  complicated  by renal  microangiopathic  hemolytic  anemiaand/or
thrombocytopenia [82].
In conclusion, SSc therapy must be tailored to the patient based on the disease subset
and organ involvement. 
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